Results for this period
First quarter1 January 2026–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the regenerative medicine support business, sales remained sluggish amid prolonged political and geopolitical turmoil in overseas markets, resulting in lower segment sales. Sales in the cell-sheet regenerative medicine business increased. On a company-wide basis, the company continued to improve its financial position through cost reductions.
A description of material events and other matters is included. While the company believes that its financing activities will prevent any difficulty in funding for the foreseeable future, there is no specific prospect yet for obtaining approval for or commercializing the first cell-sheet regenerative medicine product. The company states that circumstances exist that raise significant doubt about its ability to continue as a going concern. There are no applicable notes on the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | 13 Millions of yen (YoY -49.1%) |
| Operating profit | -250 Millions of yen |
| Ordinary income | -251 Millions of yen |
| Profit attributable to owners of the parent | -272 Millions of yen |
| Net income per share | ¥(7.24) |
| Equity ratio | End of the current fiscal period 84.1 / End of previous period 76 |
| Total assets | 2,367 Millions of yen |
| Net assets | 2,001 Millions of yen |
| Full-year earnings forecast | Net Sales 71 Millions of yen (YoY -14.9%) / Operating profit -1,225 Millions of yen / Ordinary income -1,250 Millions of yen / Net income -1,320 Millions of yen |
| Annual Dividend Forecast | 0.00 yen and sen → 0.00 yen and sen |
| Segment revenue | Regenerative Medicine Support Business ¥10,281 thousand, Cell-sheet regenerative medicine business ¥3,375 thousand |
| Segment profit | Regenerative Medicine Support Business ¥-35,574 thousand, Cell-sheet regenerative medicine business ¥-143,879 thousand |
| Depreciation and amortization | ¥0 thousand |
| Impairment loss | ¥20,321 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥20,321 thousand |
| Disclosure regarding the going concern assumption | A description of material events and other matters is included. While the company believes that its financing activities will prevent any difficulty in funding for the foreseeable future, there is no specific prospect yet for obtaining approval for or commercializing the first cell-sheet regenerative medicine product. The company states that circumstances exist that raise significant doubt about its ability to continue as a going concern. There are no applicable notes on the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | From 1 April through 30 April 2026, 1,140 of the 25th Series Stock Acquisition Rights were exercised, resulting in the issuance of 114,000 shares. The total exercise price was ¥32,037 thousand, and capital stock increased by ¥16,041 thousand. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 38,873,919 Shares |
| Treasury Shares at Period-End | 156 Shares |
| Factors Behind Changes in Business Performance | In the regenerative medicine support business, sales remained sluggish amid prolonged political and geopolitical turmoil in overseas markets, resulting in lower segment sales. Sales in the cell-sheet regenerative medicine business increased. On a company-wide basis, the company continued to improve its financial position through cost reductions. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales in the regenerative medicine support business remained sluggish amid prolonged political and geopolitical turmoil in overseas markets. Meanwhile, the company continued to improve its financial position through cost reductions and advanced research and development in the cell-sheet regenerative medicine business.